Retatrutide Study to Assess Insulin Function in Type 2 Diabetes

Type 2 Diabetes Mellitus is a chronic metabolic condition characterized by high blood sugar levels, often due to impaired insulin secretion from pancreatic β-cells and reduced insulin sensitivity in target tissues. While current treatments exist, there's a continuous need for novel therapies that can more effectively improve both aspects of glucose regulation. This Phase 1 study aims to evaluate how retatrutide impacts pancreatic α- and β-cell function and overall insulin sensitivity in adults with Type 2 Diabetes Mellitus.

As this study is currently recruiting and expected to complete in November 2026, no results are available yet. However, the primary objective is to determine if retatrutide can significantly improve the total clamp disposition index (cDI) compared to placebo after 28 weeks of treatment. The study is specifically designed to quantify the impact of retatrutide on the intricate balance between insulin secretion and insulin sensitivity in individuals with Type 2 Diabetes Mellitus. Researchers will also investigate retatrutide's effects on α- and β-cell function, aiming to identify potential improvements in the body's natural insulin production and response mechanisms. The comparison with semaglutide, a well-established GLP-1 receptor agonist, will provide valuable insights into retatrutide's relative efficacy in these critical metabolic parameters.